Medeva single isomer methylphenidate NDA expected in 1999; Apothecon licenses Medeva generic.
Executive Summary
MEDEVA/CHIROSCIENCE SINGLE ISOMER METHYLPHENIDATE NDA EXPECTED IN 1999 as part of simultaneous filings in the U.S. and Europe, Medeva told a recent meeting with securities analysts in London. Medeva and Chiroscience completed Phase I studies of the d-threo isomer of the attention deficit/hyperactivity disorder therapy methylphenidate in 1996. The companies believe the single isomer compound could have "reduced dosing and linear pharmacokinetics" compared to the racemic compound, which has "short-acting characteristics and non-linear pharmacokinetics, which make dosing and dose titration less easy and predictable," Medeva said.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth